PharmaDrug Announces Stock Ticker Symbol Change to (CSE: PHRX) Post published:July 23, 2021 Post category:Press Release
PharmaDrug Enters into Employment Agreement with Dr. Paul Van Slyke and Grants Him Options and Promotes Him to Chief Scientific Officer for All of Pharmadrug Post published:May 13, 2021 Post category:Press Release
PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation Post published:April 28, 2021 Post category:Press Release
Pharmadrug Initiates DMT Research Activities via Collaboration with the University of Michigan for Foundational DMT Research Study Post published:March 16, 2021 Post category:Press Release
PharmaDrug Announces Drug-Repurposing Expert Moshe Rogosnitzky Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board Post published:March 9, 2021 Post category:Press Release
PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board Post published:March 4, 2021 Post category:Press Release
PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney Transplantation and Expands on Its Psychedelics Strategy Post published:February 25, 2021 Post category:Press Release
PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke Post published:February 11, 2021 Post category:Press Release
PharmaDrug Appoints World-Renowned DMT Expert Dr. Steven A. Barker to Its Scientific Advisory Board for Psychedelic Pharmaceuticals Post published:February 8, 2021 Post category:Press Release